C Pfanner1, D Marazziti, L Dell'Osso
1Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, University of Pisa, Italy.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Adding risperidone to serotonin reuptake inhibitors (SRIs) effectively reduced obsessive-compulsive disorder (OCD) symptoms in treatment-resistant patients. This augmentation strategy showed promising results with manageable side effects in an open-label trial.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: